HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?
OBJECTIVE To evaluate the feasibility of conducting a large r and omized trial of HRT in symptomatic women with early-stage breast cancer . DESIGN Open r and omized study . SETTING Outpatient clinics at The Royal Marsden and St. George 's Hospitals , London . PATIENT(S ) One hundred postmenopausal women with early-stage breast cancer , experiencing vasomotor symptoms and /or vaginal dryness . INTERVENTION(S ) R and omization ( 1:1 ) to HRT or no HRT for 6 months . MAIN OUTCOME MEASURE(S ) Acceptance , continuance rates , and the reasons eligible women declined study entry . RESULT ( S ) Acceptance ( 38.8 % ) and continuance rates ( > 80 % ) were encouraging . The efficacy of HRT did not appear to be antagonized with concomitant tamoxifen . Seventy-five percent of women continued HRT after the study ended . Three women developed metastatic disease . Two used  HRT .  CONCLUSION ( S ) Despite informed consent , a national UK r and omized trial of HRT should be feasible and has now been planned . Successful implementation necessitates the provision of information about HRT and the estrogen deficiency side effects of breast cancer therapy to health professionals and women with breast cancer
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .